July 16, 2014
A New Era in Hepatitis C Treatment
Until recently, treating hepatitis C (HCV) required 24 weeks or more of weekly injections with a regimen including peginterferon alfa. These drug combinations often failed to cure the HCV infection and came with many side effects.
However, it's been a breakthrough year for HCV treatment, with many new, more effective and safer options taking the spotlight. Spearheading the way has been sofosbuvir (Sovaldi), a nucleotide polymerase inhibitor that allows for oral dosing, interferon-free treatment for many and a shorter treatment course.
But the drug's introduction -- and its high baseline price tag -- has stirred considerable debate. Let's examine the brief history of sofosbuvir and how its controversial price could impact future health care costs.
Warren Tong is the research editor for TheBody.com and TheBodyPRO.com.
Follow Warren on Twitter: @WarrenAtTheBody.
No comments have been made.
|Which HIV Treatment Regimen to Start With in 2015|
|Five Promising HIV Drugs in the Pipeline|
|What's Hot in HIV Clinical Science|
|This Week in HIV Research: Editing Human CD4 Cells; Effect of Treatment on Artery Wall Thickness; Universal Treatment; and More|
|The Most Important HIV Study at IDWeek 2015|
|Health Outcomes Worse for HIV-Positive Black Men Even Despite Equal Access|